Corcept Therapeutics (NasdaqCM:CORT) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAtabak Mokari - CFOCharles Robb - Chief Business OfficerJing He - Equity Research AssociateJoe Belanoff - CEORoberto Vieira - President of OncologySean Maduck - President of EndocrinologyWilliam Guyer - Chief Development OfficerConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystSwayampakula Ramakanth - Managing Director and Senior Healthcare Equity Research Anal ...

Company Overview - Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a pharmaceutical company focused on developing and commercializing innovative products to address unmet medical needs, specializing in oral film-based drug delivery systems [2][4] - Competitors include Teva Pharmaceuticals and Viatris, which also focus on drug delivery technologies [2] Recent Developments - New Street set a price target of $12 for AQST, indicating a potential upside of approximately 193% from its trading price of $4.10 [3] - Despite receiving a Complete Response Letter (CRL) from the FDA for Anaphylm, AQST's stock has increased by 38.98%, rising by $1.15 [3][4] - The CRL highlighted deficiencies in the human factors validation study, temporarily halting discussions on labeling and post-marketing commitments [4] - AQST's stock has shown volatility, with a daily trading range between $3.79 and $4.39, and has fluctuated between a high of $7.55 and a low of $2.12 over the past year [4] Market Position - AQST's market capitalization stands at approximately $500.21 million, with a trading volume of 60.81 million shares on the NASDAQ exchange [4] - The outcome of discussions to address the FDA's concerns regarding Anaphylm is crucial for the company's future, as it represents a significant opportunity in the treatment of anaphylaxis [5]

Core Viewpoint - Teva Pharmaceuticals reported Q4 and full-year 2025 results for UZEDY®, indicating strong sales performance and providing a positive outlook for 2026 [1] Group 1: Financial Performance - UZEDY® net sales for 2025 reached $191 million, with $55 million generated in the fourth quarter [1] - Teva's initial net sales outlook for UZEDY® in 2026 is projected to be between $250 million and $280 million [1] Group 2: Royalty Information - Medincell receives mid to high single-digit royalties on UZEDY® net sales [1] - Medincell is eligible for up to $105 million in royalties [1]

Company Overview - Royalty Pharma plc (NASDAQ:RPRX) specializes in acquiring royalties for various drugs and funding new research in the biotech sector, with a diverse portfolio that includes treatments for cancer and rare diseases [2] Recent Developments - On January 11, Royalty Pharma announced a funding agreement with Teva Pharmaceuticals to expedite the clinical development of TEV-'408, an anti-IL-15 antibody aimed at treating several autoimmune diseases [2] - CEO Pablo Legorreta emphasized the importance of addressing chronic autoimmune conditions like vitiligo, which have significant emotional and psychosocial impacts, highlighting Royalty Pharma's commitment to funding innovative therapies [2] Market Sentiment - Jim Cramer expressed a positive outlook on Royalty Pharma, noting its consistent growth and the company's role in funding biotechnology, indicating strong confidence in its business model [1]

Core Insights - Corcept Therapeutics is focused on developing drugs for severe metabolic and oncologic disorders, particularly in cortisol modulation therapies [1] - The company faces competition from Teva Pharmaceuticals and Mylan in similar therapeutic areas [1] Stock Performance - Analyst Swayampakula Ramakanth from H.C. Wainwright set a new price target of $105 for CORT, indicating a potential increase of approximately 46.8% from the current price of $41.47 [2][6] - Corcept's stock has seen a significant increase, with trading volume reaching over 3 million shares following successful results from the ROSELLA Phase 3 trial [3][6] - The current stock price is $41.61, reflecting a 14.60% increase with a change of $5.30, and the stock has fluctuated between a low of $40.46 and a high of $43.50 during the day [5] Clinical Trial Results - The ROSELLA Phase 3 trial tested relacorilant and nab-paclitaxel in treating platinum-resistant ovarian cancer, showing a 35% reduction in the risk of death for patients receiving the combination therapy [3][6] - The median overall survival for patients treated with relacorilant was 16 months, compared to 11.9 months for those on nab-paclitaxel alone, marking an improvement of 4.1 months [4][6] - The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy [4] Market Capitalization - Corcept's market capitalization stands at approximately $4.38 billion, with today's trading volume at 4,189,821 shares on the NASDAQ exchange [5]

Core Insights - Halozyme Therapeutics, Inc. will host an Investor Conference Call on January 28, 2026, to discuss preliminary unaudited full year 2025 revenue results, updated financial guidance for 2026-2028, and a business update [1] Group 1: Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery solutions [3] - The company is known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, impacting over one million patients through ten commercialized products across more than 100 global markets [3] - Halozyme has partnerships with leading pharmaceutical companies, including Roche, Takeda, Pfizer, and others, to utilize its drug delivery technology [3] Group 2: Product Development - Halozyme is developing Hypercon™, a microparticle technology aimed at enhancing drug concentration and reducing injection volume, which broadens the scope of therapeutics for subcutaneous delivery [4] - The company also focuses on drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence [5] - Halozyme has two proprietary commercial products, Hylenex and XYOSTED, along with partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited [5] Group 3: Corporate Information - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [6]

Core Insights - Lexaria Bioscience Corp. has made significant advancements in oral drug delivery technology, particularly in the GLP-1 sector, utilizing its proprietary DehydraTECH™ (DHT) technology [3][11][60] - The company reported a substantial increase in the market for GLP-1 drugs, with worldwide revenues rising from $34.4 billion in 2024 to $51.9 billion in 2025, marking a 51% year-over-year growth [8] - Lexaria's DHT technology has shown promising results in reducing adverse events (AEs) associated with GLP-1 drugs, which are primarily injectable, thus presenting a significant market opportunity [12][14][58] 2025 Highlights - In 2025, Lexaria focused its resources on studying its DHT technology with the three leading GLP-1 drugs: semaglutide, tirzepatide, and liraglutide [5][6] - The company completed its first Phase 1b registrational study in Australia, achieving a gross total of $9.5 million through three equity raises [6][49] - Lexaria's DHT technology demonstrated positive results across all R&D studies conducted in 2025, including significant reductions in AEs [6][58] Market Dynamics - The GLP-1 drug market is becoming increasingly competitive, with new companies and products emerging regularly, and existing drugs expanding their indications beyond diabetes and weight loss [9] - Despite the overall market growth, the orally-delivered segment of GLP-1 drugs has seen limited revenue growth, with only 5% of total revenues from oral products in 2025 [10] Research and Development - Lexaria's studies in 2025 included Human Pilot Studies that showed DHT-processed drugs had reduced AEs compared to their injectable counterparts, with notable reductions in gastrointestinal issues [18][29] - The company plans to leverage findings from its 2025 studies to design new R&D work in 2026, focusing on improving oral GLP-1 formulations [34][36] Collaboration and Business Development - Lexaria has extended its Material Transfer Agreement (MTA) with a pharmaceutical partner to evaluate DHT technology, allowing for continued collaboration and strategic planning [41][43] - The company is actively pursuing discussions with various pharmaceutical companies for potential partnerships, not only in the GLP-1 sector but also in other therapeutic areas [46][48] Financial Overview - Lexaria raised $9.5 million in 2025, successfully capitalizing on favorable market conditions to fund its R&D activities through 2026 [49][50] - The company has sufficient funding to support its operations and marketing campaigns in 2026, despite previous stock price weaknesses [55][56] Future Outlook - Lexaria aims to develop the world's first oral version of liraglutide using DHT and is exploring additional R&D opportunities outside the GLP-1 sector [63][40] - The company is committed to advancing its DHT technology and believes it is closer to a commercial breakthrough than ever before [60][61]

Core Viewpoint - BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics for $4.8 billion, enhancing its portfolio with therapies for lysosomal storage disorders [1] Group 1: Acquisition Details - BioMarin will pay $14.50 per share for Amicus, representing a 33% premium over Amicus' stock value of $10.89 on December 18 [1] - This acquisition is the largest in BioMarin's history and has resulted in a 17.71% increase in BioMarin's stock price, from $51.95 to $61.15 [2] Group 2: Acquired Therapies - The acquisition includes rights to Amicus' Fabry disease therapy, Galafold, which generated $458.1 million in 2024, an 18% increase from 2023 [2] - Galafold is the only FDA-approved chaperone therapy for Fabry disease and has market exclusivity until January 30, 2027, following a patent litigation with Teva Pharmaceuticals [3] - BioMarin will also acquire the FDA-approved Pompe disease combination therapy, Pombiliti plus Opfolda, which generated $22 million in 2024 [4][5] Group 3: Future Growth Strategy - BioMarin has been focusing on growth in the pharmaceutical sector, undergoing significant restructuring in 2024, which included laying off 225 employees [7] - The company has adopted a strong dealmaking strategy, signing 10 deals in 2025, the highest number since 2010 according to GlobalData's Pharmaceutical Intelligence Center [7] - BioMarin is also acquiring rights to the investigational oral small molecule DMX-200, currently in Phase III trials for focal segmental glomerulosclerosis [6]

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on advancing disruptive solutions to improve patient experiences and outcomes for both emerging and established therapies [5] - The company is headquartered in San Diego, CA, with additional offices in Ewing, NJ; Minnetonka, MN; and Boston, MA [9] Leadership Appointment - Jim Lang has been elected to Halozyme's Board of Directors, bringing over 30 years of executive leadership experience in healthcare, life sciences, business services, and data analytics [1] - Dr. Helen Torley, president and CEO, expressed confidence in Mr. Lang's strategic insight and ability to drive growth, particularly through mergers and acquisitions [2] Previous Experience of Jim Lang - Mr. Lang previously served as CEO of EVERSANA, where he led the company’s growth through the acquisition of over twenty companies, culminating in a merger with Waltz Health in August 2025 [2] - He also transformed Decision Resources Group into a leading healthcare data and analytics firm through significant expansion and acquisitions [2] Current Board Positions - Mr. Lang serves on the board of Biovie, Inc., chairing both the Audit Committee and the Nominating and Corporate Governance Committee [3] - He is also on the board of OptimizeRx Corporation, acting as chair of the Compensation Committee [3] Strategic Vision - Mr. Lang expressed his honor in joining Halozyme's Board and highlighted the company's strong foundation and compelling growth strategy [4] - He aims to work with the leadership team to accelerate growth and enhance shareholder value [4] Product Innovations - Halozyme is known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, improving patient convenience and reducing treatment burden [6] - The company is developing Hypercon™, an innovative microparticle technology expected to set a new standard in drug concentration, enhancing at-home and healthcare provider administration [7] - Halozyme also develops drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence [8]

Core Insights - ALK has appointed Edward Jordan as the new Executive Vice President and head of Commercial Operations in North America, effective January 5, 2026, succeeding Søren Niegel [1] - The elevation of ALK's two key commercial regions, Europe and North America, into the Executive Leadership Team aims to strengthen the execution of ALK's Allergy+ strategy [1] Company Overview - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma, manufacturing and marketing allergy immunotherapy treatments and acute anaphylaxis treatments [5] - The company is headquartered in Hørsholm, Denmark, employs around 2,800 people worldwide, and is listed on Nasdaq Copenhagen [5] Leadership Background - Edward Jordan brings over 30 years of biopharmaceutical experience, with expertise in allergy and immunology, having worked with companies like Merck, Teva Pharmaceuticals, and DBV Technologies [2] - His experience includes leading commercial strategy, product launches, and market development, particularly in the North American market [2] Strategic Focus - President & CEO Peter Halling emphasized the importance of strong commercial execution following recent product launches, highlighting Jordan's extensive experience in commercial growth and market insights [3] - Jordan expressed his commitment to strengthening commercial execution to expand access and adoption of ALK's products across North America [3] Executive Leadership Team Composition - Following the appointment of Edward Jordan, the Executive Leadership Team now includes various executives responsible for different operational areas, reinforcing the company's strategic focus [7]